Tonsil Cancer is a type of head and neck cancer which develops in the parts of throat and
just behind the mouth. Tonsil cancer is also known as the cancer of oropharynx. One of the
common symptoms of tonsil cancer is sore throat while some other symptoms are fatigue,
hoarseness or a change of voice while speaking, ear pain, bleeding from your mouth, and
weight loss. People who drink and smoke have almost double chances of tonsil cancer. Many
times tonsil cancer is connected with a virus associated with sexual contact known as
human papillomavirus (HPV).
Increasing incidence of tonsil is major driver for the market while other factors such as
increasing awareness about this disorder, the introduction of the new treatment or therapies
and rising demand from emerging markets of Asia as well as Latin America drives the
growth of the global market. New research to cure tonsil cancer is another key driver for the
market. The global tonsil cancer market is growing moderately and is expected to continue
its growth over the forecast period.
The Global Tonsil Cancer Market is expected to grow at the CAGR of ~4.6% during the
forecast period and is estimated to reach USD 3396.3 million by 2023.
Key Players in the Global Tonsil Cancer Market
Some of the key players in this market: F. Hoffmann-La Roche Ltd (Switzerland), Amgen
Inc. (US), Novartis AG(Switzerland), Abbott (US), Beckman Coulter Inc. (US), Debiopharm
Group (Switzerland), AbbVie Inc. (US), Bayer AG (Germany, and others.
Get Exclusive Sample Copy @
https://www.marketresearchfuture.com/sample_request/4062 .
The global tonsil cancer market is segmented on the basis of type, which comprises
squamous cell carcinoma, salivary gland cancer, lymphoma, mucosal melanoma, sarcomas,
malignant fibrous histiocytoma, Peripheral Neuroectodermal Tumor (PNET), and others.
Sarcomas is further sub-segmented into chondrosarcoma, liposarcoma, synovial sarcoma,
and others.
On the basis of diagnosis, the market is segmented into physical exam, imaging tests,
removing a sample of tissue for testing, and others. Imaging tests is further sub-segmented
into Computerized Tomography (CT), Magnetic Resonance Imaging (MRI) and Positron
Emission Tomography (PET), and others.
On the basis of treatments, the market is segmented into surgery, radiation therapy,
chemotherapy, rehabilitation, and others. Surgery is further sub-segmented into transoral
surgery, transoral robotic surgery, open surgery, reconstructive surgery, and others.
Radiation therapy includes external beam radiation therapy, internal radiation therapy, and
others. Chemotherapy is further sub-segmented into alkylating agents, plant alkaloids,
antitumor antibiotics, antimetabolites, topoisomerase inhibitors, miscellaneous
antineoplastics, and others.
On the basis of end user, it is segmented into hospitals & clinics, medical research centers,
academic institutes, and others.